Payment overview · 2025
General Payments
$246.90
13 reported records · 8 companies
Healthcare provider profile · identity verified
Lance Michael Harrell, APN - BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WEST MEMPHIS, AR · NPI 1447407671
Verified facts
What the public records show
CMS Open Payments records show Lance Michael Harrell, APN - BC received $246.90 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.79 | 23.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.29 | 15.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.16 | 13.8% | 2 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $30.70 | 12.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.60 | 12.0% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.69 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.32 | 7.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.35 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $246.90 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $42.36 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.60 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 699 | 154 |
| Alprazolam | Alprazolam | 502 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 338 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 96 |
| Gabapentin | Gabapentin | 238 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 224 | 67 |
| Potassium Chloride | Potassium Chloride | 192 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 56 |
| Furosemide | Furosemide | 174 | 54 |
| Azithromycin | Azithromycin | 167 | 131 |
| Meloxicam | Meloxicam | 163 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 36 |
| Tramadol Hcl | Tramadol Hcl | 147 | 41 |
| Lisinopril | Lisinopril | 138 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 38 |
| Metformin Hcl Er | Metformin Hcl | 114 | 34 |
| Losartan Potassium | Losartan Potassium | 113 | 42 |
| Omeprazole | Omeprazole | 110 | 32 |
| Lorazepam | Lorazepam | 107 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 24 |
| Allopurinol | Allopurinol | 95 | 21 |
| Clonazepam | Clonazepam | 94 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 25 |
| Fluconazole | Fluconazole | 87 | 36 |
| Diazepam | Diazepam | 81 | 23 |
| Trazodone Hcl | Trazodone Hcl | 81 | 27 |
| Levofloxacin | Levofloxacin | 76 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 16 |
| Clonidine Hcl | Clonidine Hcl | 73 | 25 |
| Glipizide Er | Glipizide | 72 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 23 |
| Ozempic | Semaglutide | 70 | 20 |
| Promethazine Hcl | Promethazine Hcl | 70 | 15 |
| Ondansetron Odt | Ondansetron | 68 | 37 |
| Pregabalin | Pregabalin | 68 | 16 |
| Atenolol | Atenolol | 67 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 16 |
| Prednisone | Prednisone | 65 | 52 |
| Finasteride | Finasteride | 63 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 17 |
| Carvedilol | Carvedilol | 62 | 22 |
| Spironolactone | Spironolactone | 62 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 14 |
| Mounjaro | Tirzepatide | 60 | 15 |
| Cefdinir | Cefdinir | 59 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 24 |
| Ezetimibe | Ezetimibe | 59 | 18 |
| Metformin Hcl | Metformin Hcl | 59 | 18 |
| Sertraline Hcl | Sertraline Hcl | 58 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 18 |
| Eliquis | Apixaban | 54 | 15 |
| Famotidine | Famotidine | 53 | 16 |
| Benazepril Hcl | Benazepril Hcl | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 16 |
| Simvastatin | Simvastatin | 50 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 17 |
| Bupropion Xl | Bupropion Hcl | 47 | 12 |
| Klor-Con M20 | Potassium Chloride | 39 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 28 |
| Celecoxib | Celecoxib | 32 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Methocarbamol | Methocarbamol | 28 | 14 |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Armodafinil | Armodafinil | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Nystatin | Nystatin | 18 | 12 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Baclofen | Baclofen | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Torsemide | Torsemide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Naproxen | Naproxen | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $246.90 · 13 records | ABBVIE INC. | AIRSUPRA, BREZTRI, FREESTYLE LIBRE 3, Fluad, Flucelvax, LINZESS, OTEZLA, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error